Comparing efficacy of antiplatelet agents in PCI patients heterozygous to CYP2C19*2/*3 mutations

Comparing efficacy of antiplatelet agents in PCI patients heterozygous to CYP2C192/3 mutations

Bibliographic Details
Main Authors:	S. Ramesh, S. Socrates, M.A. Rajasekar, N. Senguttuvan
Format:	Article
Language:	English
Published:	Elsevier 2015-12-01
Series:	Indian Heart Journal
Online Access:	http://www.sciencedirect.com/science/article/pii/S0019483215005660

Similar Items

Incidence of mace with genotype test guided antiplatelet treatment strategy after PCI
by: S. Ramesh, et al.
Published: (2015-12-01)

Prevalence of CYP2C19 gene polymorphism in patients with acute coronary syndrome undergoing PCI
by: S. Ramesh, et al.
Published: (2014-11-01)

Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy
by: Abdullah M. Al-Rubaish, et al.
Published: (2020-06-01)

Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial
by: Xiujin Shi, et al.
Published: (2021-06-01)

Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
by: Vassos Neocleous, et al.
Published: (2014-01-01)

Incidence of major adverse cardiovascular events with genotype test guided antiplatelet treatment strategy after percutaneous coronary intervention
by: S. Ramesh, et al.
Published: (2020-11-01)

Prognosis of Atrial Fibrillation Patients Undergoing PCI According to Anticoagulants and Antiplatelet Agents
by: Gwang-Seok Yoon, et al.
Published: (2021-07-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Exome sequencing identifies compound heterozygous mutations in CYP4V2 in a pedigree with retinitis pigmentosa.
by: Yun Wang, et al.
Published: (2012-01-01)

Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI
by: Yong-zhe Guo, et al.
Published: (2021-08-01)

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan
by: Jinnai, Toshikazu
Published: (2010)

A study on the impact of CYP2C19 genotype and platelet reactivity assay on patients undergoing PCI
by: P.C. Rath, et al.
Published: (2015-03-01)

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
by: Opstad Trine B, et al.
Published: (2011-03-01)

Dual antiplatelet therapy (DAPT) in post-PCI patients beyond one year
by: A.K. Singh, et al.
Published: (2017-11-01)

The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism
by: O L Bockeria, et al.
Published: (2016-05-01)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
by: Larisa H. Cavallari, et al.
Published: (2018-04-01)

Variations in the 3′UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia
by: Vassos Neocleous, et al.
Published: (2017-01-01)

A Novel Compound Heterozygous Mutation in the CYP4V2 Gene in a Japanese Patient with Bietti’s Crystalline Corneoretinal Dystrophy
by: Yumiko Yokoi, et al.
Published: (2011-09-01)

CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE
by: A. I. Akhmetova, et al.
Published: (2017-12-01)

CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
by: Lingxin Zhang, et al.
Published: (2020-07-01)

Novel heterozygous mutations in the PGAM2 gene with negative exercise testing
by: M. Sidhu, et al.
Published: (2018-12-01)

Compound heterozygous mutations in CYP1B1 gene leads to severe primary congenital glaucoma phenotype
by: Na Song, et al.
Published: (2019-06-01)

Cerebrotendinous xanthomatosis-a case report with novel compound heterozygous mutation of CYP27A1 gene
by: Jeng Yuan, et al.
Published: (2018-12-01)

Phenotypic heterogeneity of a compound heterozygous SUCLA2 mutation
by: Gerard T. Berry
Published: (2017-09-01)

Phenotypic heterogeneity of a compound heterozygous SUCLA2 mutation
by: Josef Finsterer, et al.
Published: (2017-03-01)

Microencapsulation of an antiplatelet agent
by: Khohlokwane, Mthimkhulu
Published: (2013)

Microencapsulation of an antiplatelet agent
by: Khohlokwane, Mthimkhulu
Published: (2013)

The Effects of H2S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
by: Xianqin Wang, et al.
Published: (2013-12-01)

Cost-effectiveness of CYP2C19 genotyping to guide antiplatelet therapy for acute minor stroke and high-risk transient ischemic attack
by: Zeling Cai, et al.
Published: (2021-04-01)

A Case Report of Compound Heterozygous CYP24A1 Mutations Leading to Nephrolithiasis Successfully Treated with Ketoconazole
by: Emma Davidson Peiris, et al.
Published: (2017-12-01)

Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy
by: Yawei Yang, et al.
Published: (2020-06-01)

No influence of the polymorphisms <it>CYP2C19 </it>and <it>CYP2D6 </it>on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma
by: Vogel Ulla, et al.
Published: (2010-08-01)

Efficacy and Safety of Antiplatelet Agents for Adult Patients With Ischemic Moyamoya Disease
by: Fei Ye, et al.
Published: (2021-01-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations
by: David Isaacs, et al.
Published: (2017-06-01)

An Interdisciplinary Experience focused on Pharmacogenetics: Engaging pharmacy and physician assistant students in conversations about antiplatelet therapy with respect to CYP2C19 genotype
by: Diane M Calinski, et al.
Published: (2016-02-01)

Penetrance of eye defects in mice heterozygous for mutation of <it>Gli3 </it>is enhanced by heterozygous mutation of <it>Pax6</it>
by: Price David J, et al.
Published: (2006-10-01)

Characterisation of <it>CYP2C8</it>, <it>CYP2C9 </it>and <it>CYP2C19 </it>polymorphisms in a Ghanaian population
by: Dodoo Alexander NO, et al.
Published: (2009-12-01)